Results 24 patients were enrolled with a median clinical follow-up of 28 months. Four patients (16.7%) developed DLTs, one occurred at a SABR treated site, and all received 15Gy. On this basis the IDSMC recommended stopping the trial and the MTD was defined at 10Gy. The 2-year PFS was 21.9% (95% CI, 7.1%-41.8%) and 2-year OS was 49.6% (95% CI,…[Read more]